ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Lipid-chondroitin sulfate conjugate modified PLGA nanocarriers of salinomycin for enhanced TRAIL-mediated apoptosis in triple negative breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression, is an aggressive subtype with limited treatment options, underscoring the need for novel therapeutic strategies. This study presents the development of chondroitin sulfate-conjugated, octadecylamine-modified PLGA lipid-polymer hybrid nanoparticles (CS-SAL-LPNPs) for targeted delivery of salinomycin (SAL), a Wnt/β-catenin pathway inhibitor, to sensitize TNBC cells to apoptosis induced by TRAIL through targeted CD44 receptor-mediated uptake. Successful nanoparticle conjugation was confirmed using FTIR and NMR spectroscopy, yielding nanoparticles of 172.36 ± 5.24 nm with a zeta potential of - 26.84 ± 0.25 mV, optimal for cellular uptake and stability. The cellular uptake of CS-SAL-LPNPs was significantly enhanced, as confirmed by confocal microscopy and flow cytometry, showing a statistically significant (p < 0.05; n ≥ 3) 1.45-fold higher fluorescence intensity compared to non-targeted systems. CS-SAL-LPNPs exhibited potent cytotoxicity, with a IC
Indexed as
Identifiers
40613939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.